BPC-157 + TB-500

Why scientists study it

• The two act in different ways: BPC-157 helps blood vessels grow through the Src, Caveolin-1 and eNOS pathway, and TB-500 moves cells by way of actin and wakes up progenitor cells.
• Each one has its own animal and cell research in tendon, muscle, heart, nerve and gut models, but no trial of the pair has been published.
• Tissue repair research often mentions them together, and a 2024 review grouped BPC-157 and Thymosin Beta-4 as repair agents that may work side by side, with no data on giving both at once.

Three studies to know

2020 · Gut and Liver

Sikiric and colleagues pulled together the record on how BPC-157 protects cells. They set it within Robert’s idea of cytoprotection and Selye’s idea of how the body copes with stress, and summed up the core research on this 15-amino-acid peptide from the gut. Read the paper

2020 · Scientific Reports

Hsieh and colleagues described how BPC-157 changes the tightness of blood vessels and turns on the Src, Caveolin-1 and eNOS pathway. This is the vessel-growing action that the BPC-157 half of the pairing rests on. Read the paper

2007 · Nature

Smart and colleagues found that adult progenitor cells in the heart’s outer layer need Thymosin Beta-4 to move out and grow new blood vessels. TB-500 is a piece of that parent peptide. Read the paper

Safety and legal status

• There is no safety data yet on the pair. Both peptides are still at the animal and cell stage, and no peer-reviewed study has assessed giving them together.
• Neither is approved by the FDA, the EMA or the MHRA. The World Anti-Doping Agency bans both: BPC-157 under S0 (non-approved substances) and TB-500 under S2 (peptide hormones, growth factors and related substances).
• For laboratory research use only, not for use in people. Safety data on each one alone are limited, and combined use has not been described.